HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Microtubule active taxanes inhibit polycystic kidney disease progression in cpk mice.

Abstract
Homozygous cpk/cpk mice develop polycystic kidney disease and die of uremia between the fourth and fifth weeks of age. Cpk/cpk mice treated weekly with paclitaxel (Taxol) can live to over six months of age. This dramatic moderation of polycystic kidney disease progression has been postulated to be a result of paclitaxel's ability to stabilize microtubules. In this study, the ability of taxanes with differing abilities to promote spontaneous in vitro assembly of tubulin dimers into microtubules were tested for their ability to inhibit the progression of polycystic kidney disease in polycystic cpk/cpk mice. We found that taxanes that are active in promoting microtubule assembly, including paclitaxel, 10-deactyl-taxol and cephalomannine increased the survival of polycystic cpk/cpk mice significantly longer than control animals. In contrast, the microtubule inactive taxane baccatin-III has no effect on the progression of renal failure in cpk/cpk mice. We conclude that the ability to promote microtubule assembly may be necessary for paclitaxel and related taxanes to modulate the progression of polycystic kidney progression in cpk/cpk mice.
AuthorsD D Woo, A P Tabancay Jr, C J Wang
JournalKidney international (Kidney Int) Vol. 51 Issue 5 Pg. 1613-8 (May 1997) ISSN: 0085-2538 [Print] United States
PMID9150481 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Alkaloids
  • Taxoids
  • baccatin III
  • cephalomannine
  • 10-deacetyltaxol
  • Paclitaxel
Topics
  • Alkaloids (pharmacology)
  • Animals
  • Kidney (drug effects, pathology)
  • Mice
  • Mice, Inbred C57BL
  • Microtubules (drug effects)
  • Paclitaxel (analogs & derivatives, pharmacology, therapeutic use)
  • Polycystic Kidney Diseases (drug therapy)
  • Structure-Activity Relationship
  • Taxoids

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: